Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis

“Mini-mental state”

Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics

Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works

Inflammation and Alzheimer’s disease

Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514 · see citing works

Alzheimer's Disease Is a Synaptic Failure

Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · see citing works

Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · see citing works

Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · see citing works

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · see citing works

Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · see citing works

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160 · see citing works

Amyloid deposition as the central event in the aetiology of Alzheimer’s disease

Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · see citing works

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · see citing works

Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · see citing works

Microglial physiology: unique stimuli, specialized responses

Ransohoff, R. M., & Perry, V. H. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132528 · Cited by 1,858 · see citing works

Transmission and spreading of tauopathy in transgenic mouse brain

Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803 · see citing works

CNS synaptogenesis promoted by glia-derived cholesterol

Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711 · see citing works

Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway

Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592 · see citing works

Microglia in neurodegenerative disease

Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17 · Cited by 1,543 · see citing works

A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid

Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · see citing works

Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology

Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507 · see citing works

Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,488 · see citing works

Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431 · see citing works

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · see citing works

Greenfield's Neuropathology

(1964) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1964.tb115841.x · Cited by 1,411 · see citing works

Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · see citing works

Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes

Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · see citing works

Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · see citing works

Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329 · see citing works

Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease

DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · see citing works

APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy

Rovelet‐Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin‐Njock, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,249 · see citing works

The Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21

George‐Hyslop, P. S., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L. E., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D. A., Drachman, D. A., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,160 · see citing works

Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss

Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · see citing works

Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins

Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023 · see citing works

Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14

Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E. J., White, J. A., Bonnycastle, L. L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 941 · see citing works

Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR

McGeer, P. L., Itagaki, S., Tago, H., & McGeer, E. G. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90696-3 · Cited by 836 · see citing works

Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease

Höck, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 777 · see citing works

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753 · see citing works

Glial‐Neuronal Interactions in Alzheimer's Disease: The Potential Role of a ‘Cytokine Cycle’ in Disease Progression

Griffin, W., Sheng, J. G., Royston, M., Gentleman, S., McKenzie, J., Graham, D. I., Roberts, G., & Mrak, R. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00136.x · Cited by 751 · see citing works

Apolipoprotein E and Alzheimer disease.

Strittmatter, W. J., & Roses, A. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4725 · Cited by 699 · see citing works

Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology

Carare, R. O., Bernardes‐Silva, M., Newman, T. A., Page, A. M., Nicoll, J. A. R., Perry, V. H., & Weller, R. O. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00926.x · Cited by 665 · see citing works

Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship

Nelson, P. T., Braak, H., & Markesbery, W. R. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181919a48 · Cited by 643 · see citing works

A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease

Davies, C. A., Mann, D. M. A., Sumpter, P. Q., & Yates, P. O. (1987) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(87)90057-8 · Cited by 628 · see citing works

Glia and their cytokines in progression of neurodegeneration

Mrak, R. E., & Griffin, W. S. T. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.05.010 · Cited by 592 · see citing works

Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease

Ferrer, I., Boada, M., Guerra, M. L. S., Rey, M. J., & Costa‐Jussà, F. R. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00493.x · Cited by 567 · see citing works

Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease

DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002) · Science · doi:10.1126/science.1067568 · Cited by 563 · see citing works

Loss of the Presynaptic Vesicle Protein Synaptophysin in Hippocampus Correlates with Cognitive Decline in Alzheimer Disease

SZE, C.-I., TRONCOSO, J. C., KAWAS, C., MOUTION, P., PRICE, D. L., & MARTIN, L. J. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199708000-00011 · Cited by 562 · see citing works

A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve.

Boyles, J. K., Zoellner, C. D., Anderson, L. J., Kosik, L. M., Pitas, R. E., Weisgraber, K. H., Hui, D. Y., Mahley, R. W., Gebicke‐Haerter, P. J., & Ignatius, M. J. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113943 · Cited by 533 · see citing works

Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy

Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., & Jucker, M. (2002) · Science · doi:10.1126/science.1078259 · Cited by 511 · see citing works

Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements

Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506 · see citing works

Lymphatic drainage of the brain and the pathophysiology of neurological disease

Weller, R. O., Djuanda, E., Yow, H.-Y., & Carare, R. O. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0457-0 · Cited by 488 · see citing works

Greenfield's Neuropathology

Love, S., Louis, D. N., & Ellison, D. W. (2008) · CRC Press eBooks · doi:10.1201/b22602 · Cited by 435 · see citing works

Disaggregation of Alzheimer β-amyloid by site-directed mAb

Solomon, B., Koppel, R., Frankel, D., & Hanan, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4109 · Cited by 420 · see citing works

Clinical manifestations of cerebral amyloid angiopathy–related inflammation

Eng, J. A., Frosch, M. P., Choi, K., Rebeck, G. W., & Greenberg, S. M. (2004) · Annals of Neurology · doi:10.1002/ana.10810 · Cited by 417 · see citing works

Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis

McLaurin, J., Cecal, R., Kierstead, M. E., Tian, X., Phinney, A. L., Manea, M., French, J. E., Lambermon, M. H. L., Darabie, A. A., Brown, M. E., et al. (2002) · Nature Medicine · doi:10.1038/nm790 · Cited by 412 · see citing works

Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology

Bard, F., Barbour, R., Cannon, C., Carretto, R., Fox, M., Games, D., Guido, T., Hoenow, K., Hu, K., Johnson-Wood, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0436286100 · Cited by 411 · see citing works

APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy

Sleegers, K., Brouwers, N., Gijselinck, I., Theuns, J., Goossens, D., Wauters, J., Del‐Favero, J., Cruts, M., van Duijn, C. M., & Broeckhoven, C. V. (2006) · Brain · doi:10.1093/brain/awl203 · Cited by 406 · see citing works

A detergent-insoluble membrance compartment contains Aβ in vivo

Lee, S., Liyanage, U. K., Bickel, P. E., Xia, W., Lansbury, P. T., & Kosik, K. S. (1998) · Nature Medicine · doi:10.1038/nm0698-730 · Cited by 395 · see citing works

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage.

Wilcock, D. M., Rojiani, A. M., Rosenthal, A., Subbarao, S., Freeman, M. J., Gordon, M. N., & Morgan, D. (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-24 · Cited by 388 · see citing works

A -related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy

Scolding, N. J. (2005) · Brain · doi:10.1093/brain/awh379 · Cited by 372 · see citing works

Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD

Bayer, A. J., Bullock, R., Jones, R. W., Wilkinson, D., Paterson, K. R., Jenkins, L., Millais, S. B., & Donoghue, S. (2005) · Neurology · doi:10.1212/01.wnl.0000148604.77591.67 · Cited by 356 · see citing works

Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

Masliah, E., Hansen, L., Adame, A., Crews, L. A., Bard, F., Lee, C., Seubert, P. A., Games, D., Kirby, L., & Schenk, D. (2005) · Neurology · doi:10.1212/01.wnl.0000148590.39911.df · Cited by 355 · see citing works

Can Alzheimer disease be prevented by amyloid-β immunotherapy?

Lemere, C. A., & Masliah, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.219 · Cited by 351 · see citing works

Inflammation and neurodegenerative diseases

Griffin, W. S. T. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.2.470s · Cited by 351 · see citing works

Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease

Holtzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., Chang, L. K., Sun, Y., & Paul, S. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6179 · Cited by 349 · see citing works

Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction

Tomic, J. L., Pensalfini, A., Head, E., & Glabe, C. G. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.024 · Cited by 336 · see citing works

Mapping of a gene predisposing to early–onset Alzheimer's disease to chromosome 14q24.3

Broeckhoven, C. V., Backhovens, H., Cruts, M., Winter, G. D., Bruyland, M., Cras, P. P., & Martin, J. (1992) · Nature Genetics · doi:10.1038/ng1292-335 · Cited by 325 · see citing works

Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain

Boche, D., Zotova, E., Weller, R. O., Love, S., Neal, J. W., Pickering, R. M., Wilkinson, D., Holmes, C., & Nicoll, J. A. R. (2008) · Brain · doi:10.1093/brain/awn261 · Cited by 316 · see citing works

Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy

Weller, R. O., Boche, D., & Nicoll, J. A. R. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0498-z · Cited by 297 · see citing works

Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease.

Masliah, E., Terry, R. D., Alford, M. F., DeTeresa, R. M., & Hansen, L. A. (1991) · PubMed Central · Cited by 296 · see citing works

Reduction of Soluble Aβ and Tau, but Not Soluble Aβ Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles

Oddo, S., Vasilevko, V., Caccamo, A., Kitazawa, M., Cribbs, D. H., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608485200 · Cited by 282 · see citing works

Mis-sense mutation Val→Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease

Naruse, S., Igarashi, S., Aoki, K., Kaneko, K., Iihara, K., Miyatake, T., Kobayashi, H., Inuzuka, T., Shimizu, T., Kojima, T., et al. (1991) · The Lancet · doi:10.1016/0140-6736(91)91612-x · Cited by 282 · see citing works

Cortical and Leptomeningeal Cerebrovascular Amyloid and White Matter Pathology in Alzheimer’s Disease

Roher, A. E., Kuo, Y., Esh, C. L., Knebel, C., Weiss, N., Kalback, W. M., Luehrs, D. C., Childress, J., Beach, T. G., Weller, R. O., et al. (2003) · Molecular Medicine · doi:10.1007/bf03402043 · Cited by 275 · see citing works

Long-term intracerebral inflammatory response after traumatic brain injury

Gentleman, S. M., Leclercq, P. D., Moyes, L., Graham, D. I., Smith, C., Griffin, W. S. T., & Nicoll, J. A. R. (2004) · Forensic Science International · doi:10.1016/j.forsciint.2004.06.027 · Cited by 272 · see citing works

A locus for familial early–onset Alzhelmer's disease on the long arm of chromosome 14, proximal to the α1–antichymotrypsin gene

Mullan, M., Houlden, H., Windelspecht, M., Fidani, L., Lombardi, C., Diaz, P., Rossor, M. N., Crook, R., Hardy, J., Duff, K., et al. (1992) · Nature Genetics · doi:10.1038/ng1292-340 · Cited by 266 · see citing works

Aβ Species Removal After Aβ ₄₂ Immunization

Nicoll, J. A. R., Barton, E., Boche, D., Neal, J. W., Ferrer, I., Thompson, P., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., et al. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240466.10758.ce · Cited by 265 · see citing works

Immunization with a Nontoxic/Nonfibrillar Amyloid-β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice

Sigurdsson, E. M., Scholtzova, H., Mehta, P. D., Frangione, B., & Wısnıewskı, T. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61715-4 · Cited by 258 · see citing works

Plaque‐associated disruption of CSF and plasma amyloid‐β (Aβ) equilibrium in a mouse model of Alzheimer's disease

Demattos, R. B., Bales, K. R., Parsadanian, M., O'Dell, M. A., Foss, E. M., Paul, S. M., & Holtzman, D. M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00889.x · Cited by 253 · see citing works

The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia

Donald, J. M. M., Savva, G. M., Brayne, C., Welzel, A. T., Forster, G., Shankar, G. M., Selkoe, D. J., Ince, P. G., & Walsh, D. M. (2010) · Brain · doi:10.1093/brain/awq065 · Cited by 251 · see citing works

Cerebral amyloid angiopathy

Greenberg, S. M. (1998) · Neurology · doi:10.1212/wnl.51.3.690 · Cited by 245 · see citing works

Exercise improves cognition and hippocampal plasticity in <i>APOE</i> ɛ4 mice

Nichol, K., Deeny, S. P., Seif, J., Camaclang, K., & Cotman, C. W. (2009) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2009.02.006 · Cited by 213 · see citing works

Are Presenilins Intramembrane-Cleaving Proteases? Implications for the Molecular Mechanism of Alzheimer's Disease

Wolfe, M. S., Angeles, J. D. L., Miller, D. D., Xia, W., & Selkoe, D. J. (1999) · Biochemistry · doi:10.1021/bi991080q · Cited by 202 · see citing works

Amyloid-β Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients

Patton, R., Kalback, W. M., Esh, C. L., Kokjohn, T. A., Vickle, G. D. V., Luehrs, D. C., Kuo, Y., Lopez, J. C., Brune, D. C., Ferrer, I., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060269 · Cited by 192 · see citing works

Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice

Brendza, R. P., Bacskai, B. J., Cirrito, J. R., Simmons, K. A., Skoch, J. M., Klunk, W. E., Mathis, C. A., Bales, K. R., Paul, S. M., Hyman, B. T., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23269 · Cited by 190 · see citing works

Prototype Alzheimer’s Disease Vaccine Using the Immunodominant B Cell Epitope from β-Amyloid and Promiscuous T Cell Epitope Pan HLA DR-Binding Peptide

Agadjanyan, M. G., Ghochikyan, A., Petrushina, I., Vasilevko, V., Movsesyan, N., Mkrtichyan, M., Saing, T., & Cribbs, D. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1580 · Cited by 182 · see citing works

β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease

Buttini, M., Masliah, E., Barbour, R., Grajeda, H., Motter, R., Johnson-Wood, K., Khan, K., Seubert, P., Freedman, S., Schenk, D., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1697-05.2005 · Cited by 176 · see citing works

Apolipoprotein E and Alzheimer's Disease A Role in Amyloid Catabolism

Poirier, J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05564.x · Cited by 170 · see citing works

Untitled work

(1995) · PubMed · Cited by 167 · see citing works

Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer?s disease*1Pro-CAA position statement

Nicoll, J. A. R., Yamada, M., Frackowiak, J., Mazur‐Kolecka, B., & Weller, R. O. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.003 · Cited by 159 · see citing works

Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathology

Serrano-Pozo, A., William, C. M., Ferrer, I., Uro-Coste, E., Delisle, M.-B., Maurage, C.-A., Hock, C., Nitsch, R. M., Masliah, E., Growdon, J. H., et al. (2010) · Brain · doi:10.1093/brain/awq056 · Cited by 159 · see citing works

Amyloid-β immunisation for Alzheimer's disease

Wisniewski, T., & Konietzko, U. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70170-4 · Cited by 155 · see citing works

Amyloid-β Antibody Treatment Leads to Rapid Normalization of Plaque-Induced Neuritic Alterations

Lombardo, J. A., Stern, E. A., McLellan, M. E., Kajdasz, S. T., Hickey, G. A., Bacskai, B. J., & Hyman, B. T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-34-10879.2003 · Cited by 149 · see citing works

An Attenuated Immune Response Is Sufficient to Enhance Cognition in an Alzheimer's Disease Mouse Model Immunized with Amyloid-β Derivatives

Sigurdsson, E. M., Knudsen, E., Asuni, A. A., Fitzer‐Attas, C. J., Sage, D., Quartermain, D., Goñi, F., Frangione, B., & Wısnıewskı, T. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1344-04.2004 · Cited by 148 · see citing works

Oral vaccination with a viral vector containing Aβ cDNA attenuates age‐related Aβ accumulation and memory deficits without causing inflammation in a mouse Alzheimer model

Mouri, A., Noda, Y., Hara, H., Mizoguchi, H., Tabira, T., & Nabeshima, T. (2007) · The FASEB Journal · doi:10.1096/fj.06-7685com · Cited by 144 · see citing works

Pathophysiology of the lymphatic drainage of the central nervous system: Implications for pathogenesis and therapy of multiple sclerosis

Weller, R. O., Galea, I., Carare, R. O., & Minagar, A. (2009) · Pathophysiology · doi:10.1016/j.pathophys.2009.10.007 · Cited by 139 · see citing works

Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice

Lemere, C. A. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00044-5 · Cited by 138 · see citing works

Current progress in beta-amyloid immunotherapy

Schenk, D., Hagen, M., & Seubert, P. A. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.07.012 · Cited by 134 · see citing works

Microglia and Alzheimer’s disease

Kalaria, R. N. (1999) · Current Opinion in Hematology · doi:10.1097/00062752-199901000-00004 · Cited by 132 · see citing works

The 717Val→Ile substitution in amyloid precursor protein is associated with familial Alzheimer's disease regardless of ethnic groups

Yoshioka, K., Miki, T., Katsuya, T., Ogihara, T., & Sakaki, Y. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91011-z · Cited by 130 · see citing works

Molecular and prospective phenotypic characterization of a pedigree with familial Alzheimer's disease and a missense mutation in codon 717 of the β‐amyloid precursor protein gene

Karlinsky, H., Vaula, G., Haines, J. L., Ridgley, J., Bergeron, C., Mortilla, M., Tupler, R. G., Percy, M. E., Robitaille, Y., Noldy, N. E., et al. (1992) · Neurology · doi:10.1212/wnl.42.8.1445 · Cited by 123 · see citing works

Increased Production of β-Amyloid and Vulnerability to Endoplasmic Reticulum Stress by an Aberrant Spliced Form of Presenilin 2

Sato, N., Imaizumi, K., Manabe, T., Taniguchi, M., Hitomi, J., Katayama, T., Yoneda, T., Morihara, T., Yasuda, Y., Takagi, T., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006886200 · Cited by 121 · see citing works

Progress in the Active Immunotherapeutic Approach to Alzheimer’s Disease: Clinical Investigations into AN1792-Associated Meningoencephalitis

Pride, M. W., Seubert, P. A., Grundman, M., Hagen, M., Eldridge, J. H., & Black, R. S. (2008) · Neurodegenerative Diseases · doi:10.1159/000113700 · Cited by 118 · see citing works

The Genetics of Alzheimer's Disease

Heston, L. L. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770200114017 · Cited by 116 · see citing works

SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer' Disease: The Role of the Immune System in Clearance of Aβ from the Brain

Boche, D., & Nicoll, J. A. R. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00134.x · Cited by 104 · see citing works

Chromosome 14–encoded Alzheimer's disease: Genetic and clinicopathological description

Haltia, M., Viitanen, M. H., Sulkava, R. O., Ala‐Hurula, V., Pöyhönen, M., Goldfarb, L. G., Brown, P., Levy, E., Houlde, H., Crook, R., et al. (1994) · Annals of Neurology · doi:10.1002/ana.410360307 · Cited by 98 · see citing works

Amyloid Reduction by Amyloid- Vaccination Also Reduces Mouse Tau Pathology and Protects from Neuron Loss in Two Mouse Models of Alzheimer's Disease

Wilcock, D. M., Gharkholonarehe, N., Nostrand, W. E. V., Davis, J., Vitek, M. P., & Colton, C. A. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1339-09.2009 · Cited by 97 · see citing works

Vaccination of Alzheimer's model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages

Asuni, A. A., Boutajangout, A., Scholtzova, H., Knudsen, E., Li, Y. S., Quartermain, D., Frangione, B., Wısnıewskı, T., & Sigurdsson, E. M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05149.x · Cited by 91 · see citing works

ApoE isoform-dependent changes in hippocampal synaptic function

Korwek, K. M., Trotter, J. H., LaDu, M. J., Sullivan, P. M., & Weeber, E. J. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-21 · Cited by 89 · see citing works

Tau-Focused Immunotherapy for Alzheimers Disease and Related Tauopathies

Sigurdsson, E. M. (2009) · Current Alzheimer Research · doi:10.2174/156720509789207930 · Cited by 87 · see citing works

Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer’s disease

Boche, D., Donald, J., Love, S., Harris, S., Neal, J. W., Holmes, C., & Nicoll, J. A. R. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0705-y · Cited by 85 · see citing works

Gene Vaccination to Bias the Immune Response to Amyloid-β Peptide as Therapy for Alzheimer Disease

Qu, B. (2004) · Archives of Neurology · doi:10.1001/archneur.61.12.1859 · Cited by 80 · see citing works

Screening for mutations in the open reading frame and promoter of the β-amyloid precursor protein gene in familial Alzheimer's disease: identification of a further family with APP717 Val→lle

Fidani, L., Rooke, K., Chartier‐Harlin, M., Hughes, D. J., Tanzi, R., Mullan, M., Roques, P. K., Rossor, M. N., Hardy, J., & Goate, A. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.3.165 · Cited by 75 · see citing works

Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease

Chauhan, N. B. (2003) · Journal of Lipid Research · doi:10.1194/jlr.r300010-jlr200 · Cited by 72 · see citing works

Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-β peptide

Istrin, G., Bosis, E., & Solomon, B. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20886 · Cited by 70 · see citing works

Inflammation and Alzheimer disease: The good, the bad and the ugly

Weninger, S. C., & Yankner, B. A. (2001) · Nature Medicine · doi:10.1038/87839 · Cited by 69 · see citing works

Absence of β-Amyloid Deposits After Immunization in Alzheimer Disease With Lewy Body Dementia

Bombois, S., Maurage, C., Gompel, M., Deramecourt, V., Mackowiak‐Cordoliani, M., Black, R. S., Lavielle, R., Delacourte, A., & Pasquier, F. (2007) · Archives of Neurology · doi:10.1001/archneur.64.4.583 · Cited by 69 · see citing works

Ageing and dementia

Lowe, J. S., Mirra, S. S., Hyman, B. T., & Dickson, D. W. (2008) · CRC Press eBooks · doi:10.1201/b13319-15 · Cited by 68 · see citing works

Altered synaptic plasticity in hippocampal CA1 area of apolipoprotein E deficient mice

Krugers, H. J., Mulder, M. T., Korf, J., Havekes, L. M., de Kloet, E. R., & Joëls, M. (1997) · Neuroreport · doi:10.1097/00001756-199707280-00018 · Cited by 68 · see citing works

The role of apolipoproteins in lipid transport processes

Alaupovic, P. (1982) · La Ricerca in Clinica e in Laboratorio · doi:10.1007/bf02909305 · Cited by 58 · see citing works

Population Variation in Glial Fibrillary Acidic Protein Levels in Brain Ageing: Relationship to Alzheimer-Type Pathology and Dementia

Wharton, S. B., O'Callaghan, J. P., Savva, G. M., Nicoll, J. A. R., Matthews, F. E., Simpson, J. E., Forster, G., Shaw, P. J., Brayne, C., & Ince, P. G. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000217729 · Cited by 58 · see citing works

Antibody-Mediated Clearance of Amyloid-β Peptide from Cerebral Amyloid Angiopathy Revealed by QuantitativeIn VivoImaging

Prada, C. M., Garcı́a-Alloza, M., Betensky, R. A., Zhang-Nunes, S., Greenberg, S. M., Bacskai, B. J., & Frosch, M. P. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.5426-06.2007 · Cited by 56 · see citing works

Prevention and Reduction of AD‐type Pathology in PDAPP Mice Immunized with Aβ1–42

Games, D., Bard, F., Grajeda, H., Guido, T., Khan, K., Soriano, F., Vasquez, N. J., Wehner, N., Johnson‐Wood, K., Yednock, T. A., et al. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06936.x · Cited by 50 · see citing works

APP717 and Alzheimer's disease in Italy

Sorbi, S., Nacmias, B., Forleo, P., Piacentini, S., Amaducci, L. A., & Provinciali, L. (1993) · Nature Genetics · doi:10.1038/ng0593-10 · Cited by 43 · see citing works

Altered long-term potentiation in the hippocampus of apolipoprotein E-deficient mice

Veinbergs, I., Jung, M. W., Young, S. J., Uden, E. V., Groves, P. M., & Masliah, E. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00399-1 · Cited by 42 · see citing works

Regulation of hippocampal cholesterol metabolism by apoE and environmental stimulation

Levi, O., Lütjohann, D., Devir, A., von Bergmann, K., Hartmann, T., & Michaelson, D. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03441.x · Cited by 39 · see citing works

Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid β-protein and GM-CSF

Kim, H., Cao, Y., Kong, F.-K., Kampen, K. R. V., Lewis, T. L., Ma, Z., Tang, D.-C. C., & Fukuchi, K.-I. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.12.015 · Cited by 39 · see citing works

APOE gene polymorphism as a risk factor for cerebral amyloid angiopathy-related hemorrhage.

Nicoll, J. A. R., & McCarron, M. O. (2001) · PubMed · Cited by 28 · see citing works

Cervical lymph nodes are found in direct relationship with the internal carotid artery: Significance for the lymphatic drainage of the brain

Clapham, R., O’Sullivan, E. P., Weller, R. O., & Carare, R. O. (2009) · Clinical Anatomy · doi:10.1002/ca.20887 · Cited by 27 · see citing works

Patterns of synaptic and nerve cell pathology in Alzheimer's disease

Lassmann, H. (1996) · Behavioural Brain Research · doi:10.1016/0166-4328(95)00215-4 · Cited by 24 · see citing works

Biochemical Markers in Alzheimer's Disease Clinical Trials

Zetterberg, H., Mattsson, N., Shaw, L. M., & Blennow, K. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.80 · Cited by 17 · see citing works

Polypeptide conjugates comprising a β‐amyloid plaque‐specific epitope as new vaccine structures against Alzheimer's disease

Manea, M., Mező, G., Hudecz, F., & Przybylski, M. (2004) · Biopolymers · doi:10.1002/bip.20160 · Cited by 16 · see citing works

Cerebrovascular Diseases

Jellinger, K. A. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01412.x · Cited by 14 · see citing works

Impact of apoE deficiency during synaptic remodeling in the mouse olfactory bulb

Nwosu, I. C., Gairhe, S., Struble, R. G., & Nathan, B. P. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.05.117 · Cited by 12 · see citing works

The neuropathological diagnosis of Alzheimer's disease

DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · see citing works

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology &amp; Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · see citing works

Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease

Prinz, M., & Priller, J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3722 · Cited by 1,329 · see citing works

Microglial priming in neurodegenerative disease

Perry, V. H., & Holmes, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.38 · Cited by 1,127 · see citing works

Tau-targeting therapies for Alzheimer disease

Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · see citing works

Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways

Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0281-2 · Cited by 947 · see citing works

The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives

Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786 · see citing works

The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics

Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742 · see citing works

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70015-7 · Cited by 512 · see citing works

Alzheimer disease therapy—moving from amyloid-β to tau

Giacobini, E., & Gold, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.223 · Cited by 483 · see citing works

Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease

de la Monte, S. M. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 446 · see citing works

Animal Models of Alzheimer Disease

LaFerla, F. M., & Green, K. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006320 · Cited by 419 · see citing works

Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics

Hampel, H., Elhage, A., Cho, M., Apostolova, L. G., Nicoll, J. A. R., & Atri, A. (2023) · Brain · doi:10.1093/brain/awad188 · Cited by 412 · see citing works

Review: sporadic cerebral amyloid angiopathy

Attems, J., Jellinger, K., Thal, D. R., & Van Nostrand, W. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01137.x · Cited by 371 · see citing works

Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies

Nelson, P. T., Head, E., Schmitt, F. A., Davis, P. R., Neltner, J. H., Jicha, G. A., Abner, E. L., Smith, C. D., Van Eldik, L. J., Kryscio, R. J., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0826-y · Cited by 365 · see citing works

Cognitive symptoms of Alzheimer’s disease: clinical management and prevention

Joe, E., & Ringman, J. M. (2019) · BMJ · doi:10.1136/bmj.l6217 · Cited by 325 · see citing works

Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: Implications for early intervention and therapeutics

Mao, P., & Reddy, P. H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.005 · Cited by 311 · see citing works

Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4363-10.2010 · Cited by 272 · see citing works

Anti–amyloid β autoantibodies in cerebral amyloid angiopathy–related inflammation: Implications for amyloid‐modifying therapies

Piazza, F., Greenberg, S. M., Savoiardo, M., Gardinetti, M., Chiapparini, L., Raicher, I., Nitríni, R., Sakaguchi, H., Brioschi, M., Billo, G., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23857 · Cited by 237 · see citing works

Emerging Concepts in Alzheimer's Disease

Vinters, H. V. (2014) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163927 · Cited by 232 · see citing works

A review on advances of treatment modalities for Alzheimer's disease

Thoe, E. S., Fauzi, A., Tang, Y.-Q., Chamyuang, S., & Chia, A. Y. Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119129 · Cited by 224 · see citing works

Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease

Nicoll, J. A. R., Buckland, G. R., Harrison, C. H., Page, A. M., Harris, S., Love, S., Neal, J., Holmes, C., & Boche, D. (2019) · Brain · doi:10.1093/brain/awz142 · Cited by 205 · see citing works

Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance

Congdon, E. E., Gu, J., Sait, H. B. R., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.491001 · Cited by 195 · see citing works

APOE-ε2 and APOE-ε4 Correlate With Increased Amyloid Accumulation in Cerebral Vasculature

Nelson, P. T., Pious, N. M., Jicha, G. A., Wilcock, D. M., Fardo, D. W., Estus, S., & Rebeck, G. W. (2013) · Journal of Neuropathology &amp; Experimental Neurology · doi:10.1097/nen.0b013e31829a25b9 · Cited by 150 · see citing works

The transcription factor PU.1 is critical for viability and function of human brain microglia

Smith, A. M., Gibbons, H. M., Oldfield, R. L., Bergin, P. M., Mee, E. W., Faull, R. L. M., & Dragunow, M. (2013) · Glia · doi:10.1002/glia.22486 · Cited by 141 · see citing works

Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?

Bayer, T. A. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.03.007 · Cited by 141 · see citing works

The endocytic pathway in microglia during health, aging and Alzheimer’s disease

Solé-Domènech, S., Cruz, D. L., Capetillo-Zarate, E., & Maxfield, F. R. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.07.002 · Cited by 133 · see citing works

BACE inhibition-dependent repair of Alzheimer’s pathophysiology

Keskin, A. D., Kekuš, M., Adelsberger, H., Neumann, U., Shimshek, D. R., Song, B., Zott, B., Peng, T., Förstl, H., Staufenbiel, M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708106114 · Cited by 125 · see citing works

Robust amyloid clearance in a mouse model of Alzheimer’s disease provides novel insights into the mechanism of amyloid-β immunotherapy

Wang, A., Das, P., Switzer, R. C., Golde, T. E., & Jankowsky, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5077-10.2011 · Cited by 118 · see citing works

Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease

Pasquier, F., Sadowsky, C., Holstein, A. R., Prince, G. L., Peng, Y., Jackson, N. M., Fox, N. C., Ketter, N., Liu, E., Ryan, J. M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150376 · Cited by 105 · see citing works

Peptides, Peptidomimetics, and Carbohydrate–Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer’s Disease

Ryan, P., Patel, B., Makwana, V., Jadhav, H. R., Kiefel, M. J., Davey, A. K., Reekie, T. A., Rudrawar, S., & Kassiou, M. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00185 · Cited by 99 · see citing works

Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta

Cohen, A. D., Rabinovici, G. D., Mathis, C. A., Jagust, W. J., Klunk, W. E., & Ikonomović, M. D. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00002-7 · Cited by 99 · see citing works

Transthyretin and the brain re-visited: Is neuronal synthesis of transthyretin protective in Alzheimer's disease?

Li, X., & Buxbaum, J. N. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-79 · Cited by 100 · see citing works

Blood-Brain Barrier Dysfunction and Cerebral Small Vessel Disease (Arteriolosclerosis) in Brains of Older People

Bridges, L., Andoh, J., Lawrence, A. J., Khoong, C. H. L., Poon, W. W., Esiri, M. M., Markus, H. S., & Hainsworth, A. H. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000124 · Cited by 97 · see citing works

Blood–brain barrier leakage and perivascular inflammation in cerebral amyloid angiopathy

Kozberg, M. G., Yi, I., Freeze, W. M., Auger, C. A., Scherlek, A. A., Greenberg, S. M., & van Veluw, S. J. (2022) · Brain Communications · doi:10.1093/braincomms/fcac245 · Cited by 94 · see citing works

Rhynchophylline Loaded-mPEG-PLGA Nanoparticles Coated with Tween-80 for Preliminary Study in Alzheimer’s Disease

Xu, R., Wang, J., Xu, J., Song, X., Huang, H., Feng, Y., & Fu, C. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s236922 · Cited by 88 · see citing works

Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms

Greenberg, S. M., Bax, F., & van Veluw, S. J. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-024-01053-8 · Cited by 103 · see citing works

O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease

Ryan, P., Xu, M., Davey, A. K., Danon, J. J., Mellick, G. D., Kassiou, M., & Rudrawar, S. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00143 · Cited by 84 · see citing works

Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies

Moore, K. B. E., Hung, T.-J., & Fortin, J. S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103487 · Cited by 86 · see citing works

Anti-Human α-Synuclein N-Terminal Peptide Antibody Protects against Dopaminergic Cell Death and Ameliorates Behavioral Deficits in an AAV-α-Synuclein Rat Model of Parkinson’s Disease

Shahaduzzaman, M., Nash, K. R., Hudson, C., Masroor, S., Grimmig, B. A., Lin, X., Bai, G., Liu, H., Ugen, K. E., Cao, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116841 · Cited by 81 · see citing works

Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy

Vasilevko, V., Passos, G. F., Quiring, D., Head, E., Kim, R. C., Fisher, M., & Cribbs, D. H. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05786.x · Cited by 72 · see citing works

Innate Immunity in Alzheimer’s Disease: A Complex Affair

Guillot‐Sestier, M., & Town, T. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312050008 · Cited by 71 · see citing works

Aβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy

Sakai, K., Boche, D., Carare, R., Johnston, D., Holmes, C., Love, S., & Nicoll, J. A. R. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1340-9 · Cited by 72 · see citing works

Animal models of cerebral amyloid angiopathy

Jäkel, L., Nostrand, W. E. V., Nicoll, J. A. R., Werring, D. J., & Verbeek, M. M. (2017) · Clinical Science · doi:10.1042/cs20170033 · Cited by 69 · see citing works

IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia

Kile, S. J., Au, W. J., Parise, C. A., Rose, K., Donnel, T., Hankins, A. I., Chan, M., & Ghassemi, A. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311486 · Cited by 67 · see citing works

Immunotherapies for Alzheimer’s Disease—A Review

Valiukas, Z., Ephraim, R., Tangalakis, K., Davidson, M., Apostolopoulos, V., & Feehan, J. (2022) · Vaccines · doi:10.3390/vaccines10091527 · Cited by 65 · see citing works

Preventive and therapeutic types of environmental enrichment counteract beta amyloid pathology by different molecular mechanisms.

Herring, A., Lewejohann, L., Panzer, A., Donath, A., Kroll, O., Sachser, N., Paulus, W., & Keyvani, K. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.03.007 · Cited by 55 · see citing works

Review: Neuropathology and behavioural features of transgenic murine models of Alzheimer's disease

Ameen‐Ali, K. E., Wharton, S. B., Simpson, J. E., Heath, P. R., Sharp, P. S., & Berwick, J. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12440 · Cited by 58 · see citing works

Loss of P2Y2 Nucleotide Receptors Enhances Early Pathology in the TgCRND8 Mouse Model of Alzheimer's Disease

Ajit, D., Woods, L. T., Camden, J. M., Thebeau, C. N., El-Sayed, F. G., Greeson, G. W., Erb, L., Petris, M. J., Miller, D. C., Sun, G. Y., et al. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8577-5 · Cited by 58 · see citing works

Microglial Amyloid- β 1-40 Phagocytosis Dysfunction Is Caused by High-Mobility Group Box Protein-1: Implications for the Pathological Progression of Alzheimer’s Disease

Takata, K., Takada, T., Ito, A., Asai, M., Tawa, M., Saito, Y., Ashihara, E., Tomimoto, H., Kitamura, Y., & Shimohama, S. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/685739 · Cited by 58 · see citing works

p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice

Walls, K. C., Ager, R. R., Vasilevko, V., Cheng, D., Medeiros, R., & LaFerla, F. M. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.05.047 · Cited by 58 · see citing works

Antibody-based therapy in Alzheimer's disease

Pul, R., Dodel, R. C., & Stangel, M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.552884 · Cited by 58 · see citing works

Alzheimer disease neuropathology in a patient previously treated with aducanumab

Plowey, E. D., Bussière, T., Rajagovindan, R., Sebalusky, J., Hamann, S., von Hehn, C., Castrillo‐Viguera, C., Sandrock, A. W., Haeberlein, S. B., van Dyck, C. H., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02433-4 · Cited by 59 · see citing works

Therapeutic targets of brain insulin resistance in sporadic Alzheimer s disease

de la Monte, S. M. (2012) · Frontiers in Bioscience-Elite · doi:10.2741/e482 · Cited by 56 · see citing works

tPA Deficiency Underlies Neurovascular Coupling Dysfunction by Amyloid-β

Park, L., Zhou, J., Koizumi, K., Wang, G., Anfray, A., Ahn, S. J., Seo, J., Zhou, P., Zhao, L., Paul, S. M., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1140-20.2020 · Cited by 54 · see citing works

The hunt for brain Aβ oligomers by peripherally circulating multi-functional nanoparticles: Potential therapeutic approach for Alzheimer disease

Mancini, S., Minniti, S., Gregori, M., Sancini, G., Cagnotto, A., Couraud, P., Ordóñez‐Gutiérrez, L., Wandosell, F. G., Salmona, M., & Re, F. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.09.003 · Cited by 54 · see citing works

Nanomedicine in Alzheimer's disease: Amyloid beta targeting strategy

Tosi, G., Pederzoli, F., Belletti, D., Vandelli, M. A., Forni, F., Duskey, J. T., & Ruozi, B. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.001 · Cited by 53 · see citing works

Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development

Savonenko, A. V., Melnikova, T., Hiatt, A., Li, T., Worley, P. F., Troncoso, J. C., Wong, P. C., & Price, D. L. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.211 · Cited by 52 · see citing works

Patterns of cerebral amyloid angiopathy define histopathological phenotypes in A lzheimer's disease

Allen, N., Robinson, A., Snowden, J. S., Davidson, Y. S., & Mann, D. M. A. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12070 · Cited by 49 · see citing works

Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease

Suzanne, M. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/482 · Cited by 50 · see citing works

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges

Cynis, H., Frost, J. L., Crehan, H., & Lemere, C. A. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0115-2 · Cited by 48 · see citing works

Endothelin receptor antagonists: Potential in Alzheimer's disease

Palmer, J. C., & Love, S. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.12.008 · Cited by 47 · see citing works

Alzheimer’s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules

Davtyan, H., Zagorski, K., Rajapaksha, H., Hovakimyan, A., Davtyan, A., Petrushina, I., Kazarian, K., Cribbs, D. H., Petrovsky, N., Agadjanyan, M. G., et al. (2016) · Scientific Reports · doi:10.1038/srep28912 · Cited by 47 · see citing works

A Quantum Dot Probe Conjugated with Aβ Antibody for Molecular Imaging of Alzheimer’s Disease in a Mouse Model

Feng, L., Long, H., Liu, R.-K., Sun, D., Liu, C., Long, L., Li, Y., Chen, S., & Xiao, B. (2013) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-013-9943-6 · Cited by 45 · see citing works

Recent developments with tau-based drug discovery

Iqbal, K., Liu, F., & Gong, C. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1445084 · Cited by 44 · see citing works

P2Y receptors in Alzheimer's disease

Erb, L., Chen, C., Ajit, D., & Weisman, G. A. (2014) · Biology of the Cell · doi:10.1111/boc.201400043 · Cited by 43 · see citing works

Longitudinal Stability of Cerebrospinal Fluid Biomarker Levels: Fulfilled Requirement for Pharmacodynamic Markers in Alzheimer's Disease

Bastard, N. L., Aerts, L., Sleegers, K., Martin, J., Broeckhoven, C. V., Deyn, P. P. D., & Engelborghs, S. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-110029 · Cited by 41 · see citing works

Invited Review – Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials

Boche, D., & Nicoll, J. A. R. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12642 · Cited by 40 · see citing works

Dantrolene, A Treatment for Alzheimer Disease?

Li, L., & Wei, H. (2014) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000076 · Cited by 39 · see citing works

Nanoliposomes as a Therapeutic Tool for Alzheimer’s Disease

Ordóñez‐Gutiérrez, L., & Wandosell, F. G. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.00020 · Cited by 40 · see citing works

Investigating Interventions in Alzheimer's Disease with Computer Simulation Models

Proctor, C. J., Boche, D., Gray, D. A., & Nicoll, J. A. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073631 · Cited by 38 · see citing works

Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: 2. Relationship to amyloid β immunotherapy

Crane, A., Brubaker, W. D., Johansson, J. U., Trigunaite, A., Ceballos, J., Bradt, B. M., Glavis‐Bloom, C., Wallace, T. L., Tenner, A. J., & Rogers, J. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.04.015 · Cited by 34 · see citing works

Bapineuzumab Alters Aβ Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy

Roher, A. E., Cribbs, D. H., Kim, R. C., Maarouf, C. L., Whiteside, C. M., Kokjohn, T. A., Daugs, I. D., Head, E., Liebsack, C., Serrano, G. E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059735 · Cited by 34 · see citing works

Therapeutic Targeting of the Endoplasmic Reticulum in Alzheimers Disease

Chadwick, W., Mitchell, N. A., Martin, B., & Maudsley, S. R. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015055 · Cited by 34 · see citing works

Deciphering the Physiology Underlying the Rapid Clinical Effects of Perispinal Etanercept in Alzheimers Disease

Tobinick, E. L. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015073 · Cited by 34 · see citing works

Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization

Jäkel, L., Boche, D., Nicoll, J. A. R., & Verbeek, M. M. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0791-6 · Cited by 29 · see citing works

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27 · see citing works

Donanemab detects a minor fraction of amyloid-β plaques in post-mortem brain tissue of patients with Alzheimer’s disease and Down syndrome

Bouter, Y., Liekefeld, H., Pichlo, S., Westhoff, A. C., Fenn, L., Bakrania, P., & Bayer, T. A. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02418-3 · Cited by 25 · see citing works

Pharmacodynamics of Cholinesterase Inhibitors Suggests Add-on Therapy with a Low-Dose Carbamylating Inhibitor in Patients on Long-Term Treatment with Rapidly Reversible Inhibitors

Darreh‐Shori, T., Hosseini, S. M., & Nordberg, A. K. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-130845 · Cited by 23 · see citing works

Neuroinflammation

Bazan, N. G., Halabi, A., Ertel, M. K., & Petasis, N. A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-374947-5.00034-1 · Cited by 22 · see citing works

Alzheimer’s Disease: Dawn of a New Era?

Amirrad, F., Bousoik, E., Shamloo, K., Al-Shiyab, H., Nguyen, V.-H. V., & Montazeri Aliabadi, H. (2017) · Journal of Pharmacy &amp; Pharmaceutical Sciences · doi:10.18433/j3vs8p · Cited by 21 · see citing works

Familial Presenilin Mutations and Sporadic Alzheimer’s Disease Pathology: Is the Assumption of Biochemical Equivalence Justified?

Roher, A. E., Maarouf, C. L., & Kokjohn, T. A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150757 · Cited by 21 · see citing works

Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease

Bu, X., Jiao, S., Lian, Y., & Wang, Y. (2015) · Current Alzheimer Research · doi:10.2174/1567205013666151215110114 · Cited by 20 · see citing works

Harnessing the Immune System for Treatment and Detection of Tau Pathology

Congdon, E. E., Krishnaswamy, S., & Sigurdsson, E. M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132435 · Cited by 20 · see citing works

Histopathological correlates of haemorrhagic lesions on ex vivo magnetic resonance imaging in immunized Alzheimer’s disease cases

Scherlek, A. A., Kozberg, M. G., Nicoll, J. A. R., Perosa, V., Freeze, W. M., van der Weerd, L., Bacskai, B. J., Greenberg, S. M., Frosch, M. P., Boche, D., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac021 · Cited by 20 · see citing works

AMBAR, an Encouraging Alzheimer's Trial That Raises Questions

Loeffler, D. A. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00459 · Cited by 19 · see citing works

Alzheimer Disease and Cellular Mechanisms of Memory Storage

Arshavsky, Y. I. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000043 · Cited by 19 · see citing works

Biochemical and Morphological Characterization of the AβPP/PS/Tau Triple Transgenic Mouse Model and Its Relevance to Sporadic Alzheimer's Disease

Hunter, J. M., Bowers, W. J., Maarouf, C. L., Mastrangelo, M. A., Daugs, I. D., Kokjohn, T. A., Kalback, W. M., Luehrs, D. C., Valla, J., Beach, T. G., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110608 · Cited by 18 · see citing works

Perspectives in Molecular Imaging Using Staging Biomarkers and Immunotherapies in Alzheimer’s Disease

Leclerc, B., & Abulrob, A. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/589308 · Cited by 18 · see citing works

Antibody 9D5 Recognizes Oligomeric Pyroglutamate Amyloid-β in a Fraction of Amyloid-β Deposits in Alzheimer's Disease without Cross-Reactivity with other Protein Aggregates

Venkataramani, V., Wirths, O., Budka, H., Härtig, W., Kovács, G. G., & Bayer, T. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111379 · Cited by 17 · see citing works

Rapid Improvement of Canine Cognitive Dysfunction with Immunotherapy designed for Alzheimer's Disease

Bosch, M. N., Gimeno‐Bayón, J., Rodríguez, M. J., Pugliese, M., & Mahy, N. (2013) · Current Alzheimer Research · doi:10.2174/15672050113109990129 · Cited by 17 · see citing works

Smart treatment strategies for alleviating tauopathy and neuroinflammation to improve clinical outcome in Alzheimer's disease

Tatiparti, K., Sau, S., Rauf, M. A., & Iyer, A. K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.025 · Cited by 16 · see citing works

A Cross‐Sectional Study on Cerebrospinal Fluid Biomarker Levels in Cognitively Normal Elderly Subjects With or Without a Family History of Alzheimer's Disease

Liu, Z., Chen, H., Li, T., Xu, L., & Du, H. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12028 · Cited by 16 · see citing works

Alzheimer’s disease and immunotherapy: what is wrong with clinical trials?

Matsumoto, Y., & Kohyama, K. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s49923 · Cited by 12 · see citing works

Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease

Kou, J., Song, M., Pattanayak, A., Lim, J. E., Yang, J., Cao, D., Li, L., & Fukuchi, K. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.01.008 · Cited by 12 · see citing works

Effects of Microglial Cytokines on Alzheimer’s Disease-Related Phenomena

Ji, Y., Wang, X., Kalicki, C. H., Menta, B. W., Baumgardner, M., Koppel, S. J., Weidling, I. W., Ortiz, J. P., Wilkins, H., & Swerdlow, R. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180820 · Cited by 12 · see citing works

Wheat germ agglutinin enhanced cerebral uptake of anti-Aβ antibody after intranasal administration in 5XFAD mice

Chauhan, N. B., Davis, F., & Xiao, C. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.08.009 · Cited by 12 · see citing works

Active Aβ vaccination fails to enhance amyloid clearance in a mouse model of Alzheimer's disease with Aβ42-driven pathology

Nemirovsky, A., Shapiro, J., Baron, R., Kompaniets, A., & Monsonego, A. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.03.017 · Cited by 9 · see citing works

Active immunization with norovirus P particle-based amyloid-β chimeric protein vaccine induces high titers of anti-Aβ antibodies in mice

Yang, P. C., Guo, Y., Sun, Y., Yu, B., Zhang, H., Wu, J., Yu, X., Wu, H., & Kong, W. (2019) · BMC Immunology · doi:10.1186/s12865-019-0289-9 · Cited by 9 · see citing works

Magnetic Resonance Imaging-Negative Cerebral Amyloid Angiopathy: Cerebrospinal Fluid Amyloid-β42 over Amyloid Positron Emission Tomography

Pyun, J.-M., Kang, M. J., Baek, S. J., Lee, K. S., Park, Y. H., & Kim, S. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.49 · Cited by 8 · see citing works

THE PROSPECTS FOR A VACCINE FOR ALZHEIMER'S DISEASE

Nicoll, J. A. R. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308883.5

S.13.02 Immunotherapy in tauopathies

Sigurdsson, E. M. (2012) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(12)70159-1

Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization

Jäkel, L., Boche, D., Nicoll, J. A. R., & Verbeek, M. M. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0791-6 · Cited by 29 · see citing works

Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · see citing works

Effects of Abeta immunotherapy on cerebral amyloidangiopathy in Alzheimer’s disease

Boche, D., Barton, E., Neal, J., Ferrer, I., Wilkinson, D. G., Bayer, A. L., Holmes, C., Weller, R. O., & Nicoll, J. A. R. (2006) · Neuropathology and Applied Neurobiology